Amgen Lobs $167M Bid For Danish Biopharma Nuevolution
Biotechnology giant Amgen said Wednesday it lobbed a 1.6 billion Swedish kronor ($167 million) cash bid to buy Nuevolution, an offer that has already won a unanimous recommendation in favor from...To view the full article, register now.
Already a subscriber? Click here to view full article